New pancreatic cancer drug shows major survival breakthrough

Daraxonrasib nearly doubles expected lifespan in clinical trial data compared with historical outcomes.

Pancreatic cancer has long been one of medicine’s most difficult diseases to treat. Often detected only after it has already spread, the disease is known for its aggressive progression and low survival rates, leaving patients with few treatment options.

That may be starting to change with daraxonrasib, an experimental drug that has generated excitement among cancer researchers after clinical trial results showed notable improvements in survival among patients with advanced pancreatic cancer.

In a recent study in the United States involving previously treated patients, those who received daraxonrasib survived for about 15 months on average. Historically, similar patients often survive for less than half that period, making the results one of the most promising developments the field has seen in years.

The drug targets KRAS, a genetic mutation found in the vast majority of pancreatic cancers. Scientists have spent decades trying to develop effective therapies against KRAS-driven tumors, with limited success until now. Researchers say daraxonrasib represents the first potentially effective targeted treatment for a large portion of pancreatic cancer patients.

Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, daraxonrasib is designed to interfere with specific cancer-driving pathways. Researchers say this targeted approach may help better preserve quality of life while still slowing disease progression.

The drug is not considered a cure, and patients can still experience side effects such as rashes, diarrhea, nausea, and inflammation. However, doctors involved in the research describe these effects as generally manageable compared with many standard cancer treatments.

The breakthrough has also fueled hopes that similar therapies could emerge in the coming years. Researchers are already studying daraxonrasib for other solid-tumor cancers, while competing drug developers are working on next-generation treatments based on the same approach.